Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | PPM1B | O75688 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345801 | 1.00 | MAPT (0.51) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2341347 | 1.00 | MAPT (0.51) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2341343 | 1.00 | MAPT (0.51) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2375356 | 0.89 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL8891623 | 0.89 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL4221 | 0.89 | — | — | |
| SCHEMBL237380 | 0.89 | MAPT (0.60) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL17802981 | 0.88 | MAPT (0.45) | MAPTALDH1A1PPM1BPTPN1PPP1CC | |
| Hydrochloric Acid SCHEMBL28788727 | 0.87 | — | — | |
| SCHEMBL2275933 | 0.86 | MAPT (0.47) | MAPTALDH1A1PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642590-B2 | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2358714-B1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | HOFFMANN LA ROCHE (CH) | 2012-08-01 | — | — | EP | disclosed |
| EP-2358714-A1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | F. Hoffmann-La Roche AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010057795-A1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-27 | — | — | WO | disclosed |
| US-20100125066-A1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142555-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-7625891-B2 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008119663-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080249087-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125066-A1 | ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, OXTR | MAPT 4699/4885ALDH1A1 298/4885PPM1B 2594/4885 |
| US-20080249087-A1 | Heterocylic antiviral compounds | CCR5, CCR1, CXCR1 | MAPT 4662/4885ALDH1A1 339/4885PPM1B 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.